There is no way out we can to talk about Seattle Genetics without talking about Dr. Siegall. His education and in-depth knowledge in Genetics, has given Dr. Clay Siegall the best leadership skills. He is the best performing CEO and co-founder of Seattle Genetics. He has also worked in more than five companies which include PDL Biopharma, Genentech and National Institutes of Health just to mention some. He has worked on the board and advisors roles in three organizations. For instance, Alder Biopharmaceuticals had him working on the board of directors, Mirna Therapeutics as a member of the council and Fred Hutchinson Cancer Research Center in the board of governors.
Digging back to history, Dr. Siegall has helped Seattle Genetics much since it was started in 1998. His effort in the leading the company can be seen due to its success. Seattle Genetics aims to fight against cancer in all possible ways. It is the first in the therapy industry to develop an FDA approve antibody-drug conjugate. Also, it has partnered with other organizations like Genentech, Bayer, and Pfizer in developing a series of more than 20 drugs that are approved.
With his Ph.D. in genetics, Dr. Siegall has helped Seattle Genetics from its startup stage to where it is now. If Seattle Genetics goes with the same pace of being the best in cancer research, it will come out to be the most influential in the company in the 21st century in drug production industry. Dr. Siegall says that old ways of treating cancer should be avoided and focus based on the current and efficient therapies. This is a big dream that Dr. Siegall wants to be true one day.
His interest in medicine and particularly in fighting diseases like cancer has made him what he is now. He hated sickness when his family member developed chemotherapy. He wanted to look for an alternative way of dealing with cancer instead of conducting expensive surgeries. So far, he has achieved this goal through Seattle Genetics where is current running intensive research projects. With his degree in zoology, he is able in achieving much regarding cell study.